Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

Area of Science:

• Hepatobiliary Cancers
• Oncology Therapeutics
• Health Services Research

Background:

• Phase III trials indicate sorafenib improves survival in advanced hepatocellular carcinoma (HCC).
• Narrow eligibility criteria in trials may limit generalizability of sorafenib's effectiveness to broader HCC patient populations.
• This study evaluates sorafenib's real-world effectiveness in Medicare beneficiaries with advanced HCC.

Purpose of the Study:

• To assess the effectiveness of initial sorafenib treatment compared to no treatment in advanced HCC patients covered by Medicare.
• To determine if sorafenib provides a survival advantage in a broader, non-trial population of HCC patients.

Main Methods:

• Utilized the Surveillance, Epidemiology, and End Results-Medicare database for advanced HCC patients diagnosed between 2008-2011.
• Employed propensity score matching to compare sorafenib initiators (n=223) with a non-treatment group (n=223).
• Assessed survival outcomes using Cox proportional hazards and binomial regression with a 60-day landmark.

Main Results:

• Median survival was 3 months post-sorafenib initiation, with no significant difference compared to untreated patients (3 vs. 2 months from landmark).
• Sorafenib showed a nonsignificant reduction in 3-month mortality (44% vs. 51%).
• No survival benefit was observed beyond 3 months for sorafenib-treated patients.

Conclusions:

• Sorafenib offers minimal survival benefit in newly diagnosed Medicare beneficiaries with advanced HCC, suggesting limited generalizability from clinical trials.
• The high cost and symptom burden of sorafenib must be weighed against its minimal effectiveness in this population.
• Supportive care should be considered a viable alternative to sorafenib, especially for patients with poor performance status or advanced cirrhosis.